Annovis Bio, Inc. Reports Fiscal Year 2025 Financial Results and Provides Corporate Updates

Annovis Bio, Inc. announced its financial results for the fiscal year 2025 and provided corporate updates. The company initiated a pivotal Phase 3 clinical trial for buntanetap in early Alzheimer's disease (AD) and reported encouraging data from previous AD and Parkinson's disease (PD) programs, showing a potential disease-modifying signal. A new open-label extension study in PD was also initiated. The company reported a net loss of $28.9 million for FY2025, with research and development expenses totaling $25.2 million and general and administrative expenses at $4.5 million. Cash and cash equivalents were $19.5 million as of December 31, 2025, with an estimated runway into the third quarter of 2026. Key developments included patent transfers for a new crystal form of buntanetap, extending intellectual property protection until 2047, and participation in major scientific and investor conferences. The management team was expanded with the appointment of a new CFO and Director of Biostatistics.